文献速递乳房整形与再造

乳房胸肌前重建中GalaFLEX-AlloDerm复合体的安全性评估

Evaluation of the Safety of a GalaFLEX-AlloDerm Construct in Prepectoral Breast Reconstruction.
PubMed 文献 · Plast Reconstr Surg · 2022-09-28

这项回顾性研究纳入接受即刻、扩张器-假体、胸肌前乳房重建的连续患者,比较GalaFLEX-AlloDerm复合体与单用AlloDerm的安全性。单用AlloDerm组128例(249侧乳房),复合体组135例(250侧乳房)。总体并发症发生率单用AlloDerm组为7.6%,GalaFLEX-AlloDerm组为6.4%,感染、主要皮肤坏死、血清肿、包膜挛缩、假体暴露/挤出及假体丢失在复合体组均≤3.0%且与单用组无显著差异。作者认为GalaFLEX生物可吸收基质是两阶段胸肌前重建中较便宜的替代选择,安全性相当,但需进一步长期数据和临床经验。

要点

  • 单用AlloDerm组总体并发症发生率为7.6%,GalaFLEX-AlloDerm组为6.4%。
  • 复合体组感染、主要皮肤坏死、血清肿、包膜挛缩、假体暴露/挤出及假体丢失均≤3.0%。
  • 上述并发症在复合体组与单用AlloDerm组无显著差异。

核心结论

  • GalaFLEX生物可吸收基质是两阶段胸肌前重建中较便宜的替代选择,安全性相当。
  • 需进一步长期数据和临床经验来更好地了解该基质用于乳房重建的安全性。

研究设计与样本

  • 回顾性研究,纳入接受即刻、扩张器-假体、胸肌前乳房重建的连续患者。
  • 患者分为两组:接受GalaFLEX-AlloDerm复合体者与单用AlloDerm者。
  • 单用AlloDerm组128例(249侧乳房),GalaFLEX-AlloDerm组135例(250侧乳房)。
  • 在GalaFLEX-AlloDerm重建中,扩张器下三分之一由AlloDerm覆盖,其余部分由GalaFLEX覆盖。
  • 比较两组重建后并发症。

主要发现

  • 总体并发症发生率单用AlloDerm组为7.6%,GalaFLEX-AlloDerm组为6.4%。
  • GalaFLEX-AlloDerm组感染、主要皮肤坏死、血清肿、包膜挛缩、假体暴露/挤出及假体丢失发生率均≤3.0%。
  • 上述并发症在GalaFLEX-AlloDerm组与单用AlloDerm组无显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prepectoral implant-based breast reconstruction is gaining in popularity. Acellular dermal matrices are an integral part of prepectoral reconstruction. However, large quantities of acellular dermal matrix are required for total implant coverage, and the cost of acellular dermal matrices could be a deterrent to reconstruction. To minimize the cost, the authors have resorted to the use of a bioabsorbable mesh, GalaFLEX, as a partial replacement to acellular dermal matrices. This study evaluates the comparative safety of using a GalaFLEX-AlloDerm construct versus AlloDerm alone in prepectoral reconstruction. METHODS: Consecutive patients who underwent immediate, expander-implant, prepectoral breast reconstruction were included in this retrospective study. Patients were stratified into two groups: those who received the GalaFLEX-AlloDerm combination versus AlloDerm alone. In GalaFLEX-AlloDerm reconstructions, the lower third of the expander was covered by the AlloDerm, whereas the rest of the expander was covered by GalaFLEX. Complications following reconstruction were compared between the groups. RESULTS: AlloDerm alone was used in 128 patients (249 breasts) and GalaFLEX-AlloDerm was used in 135 patients (250 breasts). The rate of any complication was 7.6 percent in the AlloDerm-alone group and 6.4 percent in the GalaFLEX-AlloDerm group. The rate of infection, major skin necrosis, seroma, capsular contracture, prosthesis exposure/extrusion, and prosthesis loss were less than or equal to 3.0 percent in the GalaFLEX-AlloDerm group and did not differ significantly from those in the AlloDerm-only group. CONCLUSIONS: GalaFLEX bioabsorbable matrix is a less costly alternative to acellular dermal matrices in two-stage, prepectoral reconstruction with comparable safety outcomes. Further long-term data and clinical experience are needed to better understand the safety of this matrix for use in breast reconstruction. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Sigalove S, O'Rorke E, Maxwell GP, et al. Evaluation of the Safety of a GalaFLEX-AlloDerm Construct in Prepectoral Breast Reconstruction. Plast Reconstr Surg. 2022. PMID: 35943912. doi:10.1097/PRS.0000000000009520

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。